<DOC>
	<DOCNO>NCT00113295</DOCNO>
	<brief_summary>The purpose study examine safety efficacy quetiapine generalize anxiety disorder patient remain symptomatic despite treatment paroxetine CR .</brief_summary>
	<brief_title>Combination Paroxetine CR Quetiapine Treatment Refractory Generalized Anxiety Disorder</brief_title>
	<detailed_description>Generalized anxiety disorder ( GAD ) relatively common condition affect 5 % population , typically chronic course associate significant psychosocial impairment decrease quality life ( Schweizer , 1995 ) . Although number therapeutic agent demonstrate efficacy treatment generalize anxiety disorder , minority anxious patient experience remission initial treatment . The purpose study examine efficacy one strategy , addition quetiapine , treatment patient GAD remain refractory despite adequate treatment trial selective serotonin reuptake inhibitor ( SSRI ) . This investigator-initiated augmentation study already approve drug different indication . Quetiapine novel antipsychotic agent potent effect serotonergic , well dopaminergic receptor , favorable side effect profile standard neuroleptic , include low potential cause extrapyramidal symptom . This two phase , 18-week research study participant remain symptomatic end one phase ( 10 week ) enter next phase . In phase I , participant receive paroxetine CR ( Paxil CR ) 10 week . Participants continue anxiety symptom enter 8-week Phase II , continue take Paxil CR also randomly assign ( chance , like flip coin ) receive quetiapine ( Seroquel ) placebo ( contains active medication ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Male female outpatient , age 1872 . Primary diagnosis generalize anxiety disorder . Patients concurrent benzodiazepine enter trial remain symptomatic despite stable dos least one month Pregnant lactate woman woman child bear potential use acceptable mean birth control Patients primary diagnosis major depression , dysthymia , panic disorder social phobia . Patients current history bipolar disorder , schizophrenia psychotic condition Patients posttraumatic stress disorder obsessivecompulsive disorder current past 6 month . Patients history alcohol substance abuse dependence within last six month . Patients significant unstable medical illness . Ongoing psychotherapy direct toward treatment generalize anxiety disorder . History hypersensitivity paroxetine CR , paroxetine quetiapine . History cataract . Concurrent use psychotropic medication include buspirone antidepressant . Patients must discontinue buspirone antidepressant therapy least two week prior study entry , fluoxetine least four week prior , patient take effective medication . Concomitant use herb dietary supplement know psychotropic property , include St John 's Wort , Kava , Valerian , Gingko , Ginseng , ephedra weight loss supplement . Other agent know psychotropic property , counter medication exclusionary .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>generalize anxiety disorder</keyword>
	<keyword>pharmacotherapy</keyword>
	<keyword>treatment refractory</keyword>
	<keyword>double-blind</keyword>
</DOC>